Your browser is no longer supported. Please, upgrade your browser.
Abiomed, Inc.
IndexS&P 500 P/E60.12 EPS (ttm)4.94 Insider Own1.00% Shs Outstand45.20M Perf Week-7.46%
Market Cap13.52B Forward P/E57.08 EPS next Y5.20 Insider Trans-6.40% Shs Float44.13M Perf Month-9.99%
Income225.50M PEG3.52 EPS next Q1.06 Inst Own97.10% Short Float2.28% Perf Quarter-9.47%
Sales847.50M P/S15.95 EPS this Y-21.00% Inst Trans0.34% Short Ratio3.56 Perf Half Y11.40%
Book/sh27.91 P/B10.63 EPS next Y18.45% ROA15.90% Target Price374.00 Perf Year57.60%
Cash/sh10.68 P/C27.79 EPS next 5Y17.10% ROE18.00% 52W Range180.29 - 387.40 Perf YTD-8.45%
Dividend- P/FCF54.95 EPS past 5Y10.80% ROI17.90% 52W High-23.38% Beta1.28
Dividend %- Quick Ratio5.10 Sales past 5Y29.60% Gross Margin80.90% 52W Low64.63% ATR10.60
Employees1536 Current Ratio5.80 Sales Q/Q4.60% Oper. Margin25.90% RSI (14)35.05 Volatility3.36% 3.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.60% Profit Margin24.50% Rel Volume0.65 Prev Close295.72
ShortableYes LT Debt/Eq0.00 EarningsApr 29 BMO Payout0.00% Avg Volume282.84K Price296.81
Recom2.30 SMA20-9.87% SMA50-6.26% SMA200-1.16% Volume183,209 Change0.37%
Apr-27-20Downgrade SVB Leerink Outperform → Mkt Perform $175
Feb-12-20Downgrade Morgan Stanley Equal-Weight → Underweight $165
Feb-06-20Resumed BTIG Research Neutral
Oct-29-19Downgrade Raymond James Outperform → Mkt Perform
Aug-02-19Downgrade Morgan Stanley Overweight → Equal-Weight $325 → $215
Aug-02-19Downgrade Guggenheim Buy → Neutral
Aug-01-19Downgrade BTIG Research Buy → Neutral
Nov-07-18Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-02-18Upgrade BTIG Research Neutral → Buy
Jun-22-18Reiterated Piper Jaffray Overweight $360 → $480
Apr-04-18Initiated Goldman Buy $332
Jan-19-18Reiterated Leerink Partners Outperform $200 → $265
Oct-16-17Downgrade BTIG Research Buy → Neutral
Sep-29-17Initiated SunTrust Buy $195
Jun-08-17Resumed William Blair Outperform
Apr-06-17Upgrade Piper Jaffray Neutral → Overweight
Dec-07-16Initiated Guggenheim Buy
Oct-30-15Upgrade Raymond James Mkt Perform → Outperform
Aug-18-15Initiated Sterne Agee CRT Buy $130
Aug-12-15Reiterated The Benchmark Company Buy $96 → $129
May-04-21 09:16AM  
Apr-29-21 01:43PM  
Apr-28-21 03:57PM  
Apr-25-21 04:48PM  
Apr-23-21 11:25AM  
Apr-22-21 12:33PM  
Apr-16-21 02:23AM  
Apr-15-21 08:03AM  
Apr-10-21 06:00AM  
Apr-08-21 07:00AM  
Apr-03-21 06:40AM  
Apr-01-21 06:57AM  
Mar-31-21 07:17AM  
Mar-21-21 07:37AM  
Mar-11-21 11:40AM  
Mar-10-21 06:00AM  
Mar-04-21 09:00AM  
Mar-01-21 11:26PM  
Feb-27-21 11:30AM  
Feb-17-21 08:03AM  
Feb-11-21 11:47AM  
Feb-04-21 07:47AM  
Feb-02-21 06:20AM  
Feb-01-21 10:51AM  
Jan-31-21 01:04AM  
Jan-29-21 09:36AM  
Jan-28-21 01:51PM  
Jan-26-21 12:20PM  
Jan-14-21 07:00AM  
Jan-07-21 09:13AM  
Jan-05-21 11:40PM  
Dec-29-20 01:29PM  
Dec-23-20 06:53AM  
Dec-21-20 08:05AM  
Dec-15-20 08:03AM  
Dec-06-20 11:29PM  
Nov-25-20 07:00AM  
Nov-18-20 06:36AM  
Nov-11-20 07:00AM  
Nov-07-20 07:07AM  
Nov-05-20 08:00AM  
Oct-29-20 04:01PM  
Oct-28-20 09:53AM  
Oct-27-20 10:48AM  
Oct-26-20 07:55AM  
Oct-22-20 12:33PM  
Oct-16-20 08:05AM  
Oct-15-20 01:56PM  
Oct-14-20 11:40AM  
Oct-13-20 07:49AM  
Oct-10-20 06:39AM  
Oct-08-20 05:00PM  
Sep-30-20 04:01PM  
Sep-15-20 12:20AM  
Sep-14-20 07:00AM  
Sep-08-20 07:00AM  
Sep-05-20 11:31AM  
Aug-31-20 08:00AM  
Aug-27-20 07:24AM  
Aug-24-20 12:40PM  
Aug-18-20 12:45PM  
Aug-06-20 09:26AM  
Aug-04-20 08:50AM  
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUTTER MARTIN PDirectorFeb 17Sale314.013,7501,177,538176,510Feb 18 04:11 PM
SUTTER MARTIN PDirectorFeb 16Sale330.673,7501,240,012180,260Feb 18 04:11 PM
PUHY DOROTHY EDirectorFeb 01Sale349.475,0001,747,3472,869Feb 03 05:03 PM
Greenfield Andrew JVP, Chief Commercial OfficerJan 28Option Exercise66.255,000331,25036,930Feb 01 05:14 PM
Greenfield Andrew JVP, Chief Commercial OfficerJan 28Sale366.005,0001,830,00031,930Feb 01 05:14 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 29Sale321.005,0001,605,00026,930Dec 31 04:03 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 22Sale296.671,682498,99731,930Dec 23 04:04 PM
Greenfield Andrew JVP, Chief Commercial OfficerDec 21Sale295.635,4741,618,27933,612Dec 23 04:04 PM
SUTTER MARTIN PDirectorNov 18Sale268.34750201,255184,010Nov 19 06:16 PM
SUTTER MARTIN PDirectorNov 17Sale269.53750202,147184,760Nov 19 06:16 PM
MINOGUE MICHAEL RChairman, President, CEOAug 21Option Exercise22.4440,000897,600250,746Aug 24 05:45 PM
MINOGUE MICHAEL RChairman, President, CEOAug 21Sale306.3340,00012,253,177210,746Aug 24 05:45 PM
MINOGUE MICHAEL RChairman, President, CEOAug 20Option Exercise22.4460,0001,346,400270,746Aug 24 05:45 PM
MINOGUE MICHAEL RChairman, President, CEOAug 20Sale310.9860,00018,658,744210,746Aug 24 05:45 PM
SUTTER MARTIN PDirectorAug 19Sale312.38750234,285186,260Aug 20 04:40 PM
SUTTER MARTIN PDirectorAug 18Sale311.99750233,992187,760Aug 20 04:40 PM
THOMAS PAULDirectorAug 10Sale303.412,000606,8206,530Aug 11 04:07 PM
PUHY DOROTHY EDirectorJul 15Sale275.007,5002,062,5007,652Jul 17 04:02 PM
PUHY DOROTHY EDirectorJun 05Sale250.007,5001,875,00015,152Jun 09 04:04 PM